Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	901,099	757,598	674,020	637,941	303,575	391,729
Market Cap Growth	40.98%	12.40%	5.66%	110.14%	-22.50%	-24.14%
Enterprise Value	875,897	746,546	689,676	632,994	283,996	394,408
Last Close Price	1610.90	1304.40	1156.16	1084.68	513.88	653.35

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	24.47	21.62	19.34	20.11	15.75	14.79
Forward PE	19.61	18.02	15.91	17.77	12.19	12.83
PS Ratio	2.65	2.25	2.13	2.20	1.22	1.67
PB Ratio	2.45	2.00	2.07	2.14	1.13	1.59
P/TBV Ratio	2.83	2.31	2.36	2.46	1.31	1.85
P/FCF Ratio	32.63	26.67	34.45	-	-	13.22
P/OCF Ratio	16.77	13.71	17.17	26.20	12.72	7.81
PEG Ratio	1.05	1.44	1.36	0.78	1.63	2.09

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	2.58	2.22	2.17	2.18	1.14	1.68
EV/EBITDA Ratio	12.70	11.01	10.63	10.98	7.81	9.15
EV/EBIT Ratio	16.87	14.49	13.68	14.41	11.31	11.93
EV/FCF Ratio	31.74	26.28	35.25	-	-	13.31

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.21	0.21	0.25	0.22	0.20	0.12
Debt / EBITDA Ratio	1.14	1.18	1.26	1.14	1.43	0.65
Debt / FCF Ratio	-	2.84	4.22	-	-	0.96
Net Debt / Equity Ratio	-0.07	-0.07	0.00	0.01	-0.04	-0.07
Net Debt / EBITDA Ratio	-0.36	-0.37	0.01	0.06	-0.26	-0.40
Net Debt / FCF Ratio	-	-0.88	0.03	-0.93	55.51	-0.58
Asset Turnover	-	0.62	0.67	0.68	0.67	0.69
Inventory Turnover	-	1.24	1.33	1.42	1.45	1.26
Quick Ratio	-	1.00	0.99	0.96	0.98	1.10
Current Ratio	-	1.81	1.85	1.98	1.88	2.22
Return on Equity (ROE)	-	9.93%	11.15%	11.18%	7.50%	11.39%
Return on Assets (ROA)	-	5.95%	6.64%	6.46%	4.25%	6.10%
Return on Invested Capital (ROIC)	10.35%	10.37%	11.03%	11.33%	7.60%	11.66%
Return on Capital Employed (ROCE)	-	12.70%	14.40%	13.40%	8.80%	12.80%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	4.09%	4.63%	5.17%	4.97%	6.35%	6.76%
FCF Yield	3.06%	3.75%	2.90%	-0.54%	-0.06%	7.56%
Dividend Yield	0.51%	-	-	0.41%	0.58%	1.35%
Payout Ratio	-	6.63%	0.03%	8.31%	22.80%	9.96%
Buyback Yield / Dilution	0.25%	0.36%	0.52%	-	-	-
Total Shareholder Return	0.74%	0.36%	0.52%	0.41%	0.58%	1.35%

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error